Who
Azita Saleki-Gerhardt
Director
Company insider
Files Form 4 as: Director, Entegris; EVP, Chief Operations Officer, AbbVie.
In numbers
- Trades disclosed
- 186
- Buys
- 0
- Sells
- 21
- Bought
- $0
- Sold
- $43.2M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 4 Feb 2013
- Last trade
- 6 May 2026
- Last filed
- 8 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 May 2026filed 8 May 2026 | ENTG EntegrisSemiconductor Equipment | SEC FORM 4 Code A | —1,412 at $0.00 | filing |
| 6 May 2026filed 8 May 2026 | ENTG EntegrisSemiconductor Equipment | SEC FORM 4 Code A | —1,412 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | ABBV AbbViePharmaceuticals | SEC FORM 4 Code F | $3.8M16,309 at $232.08 | filing |
| 27 Feb 2026filed 3 Mar 2026 | ABBV AbbViePharmaceuticals | SEC FORM 4 Code F | $3.8M16,309 at $232.08 | filing |
| 18 Feb 2026filed 20 Feb 2026 | ABBV AbbViePharmaceuticals | SEC FORM 4 Code A | —17,041 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | ABBV AbbViePharmaceuticals | SEC FORM 4 Code A | —6,058 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | ABBV AbbViePharmaceuticals | SEC FORM 4 Code A | —7,074 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | ABBV AbbVieoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —20,312 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | ABBV AbbViePharmaceuticals | SEC FORM 4 Code A | —6,638 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | ABBV AbbVieoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —20,312 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | ABBV AbbViePharmaceuticals | SEC FORM 4 Code A | —17,041 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | ABBV AbbViePharmaceuticals | SEC FORM 4 Code A | —6,058 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | ABBV AbbViePharmaceuticals | SEC FORM 4 Code A | —7,074 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | ABBV AbbViePharmaceuticals | SEC FORM 4 Code A | —6,638 at $0.00 | filing |
| 12 Aug 2025filed 14 Aug 2025 | ABBV AbbVieoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | $2.3M42,370 at $54.86 | filing |
| 12 Aug 2025filed 14 Aug 2025 | ABBV AbbViePharmaceuticals | SEC FORM 4 Code M | $2.3M42,370 at $54.86 | filing |
| 12 Aug 2025filed 14 Aug 2025 | ABBV AbbViePharmaceuticals | SEC FORM 4 Sold | $8.4M42,370 at $198.42 | filing |
| 23 Apr 2025filed 25 Apr 2025 | ENTG EntegrisSemiconductor Equipment | SEC FORM 4 Code A | —2,897 at $0.00 | filing |
| 28 Feb 2025filed 4 Mar 2025 | ABBV AbbViePharmaceuticals | SEC FORM 4 Code F | $3.5M17,056 at $205.02 | filing |
| 13 Feb 2025filed 18 Feb 2025 | ABBV AbbVieoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
News
AbbVie vs. Bristol Myers: Is AbbVie's Valuation Premium Worth Paying?ABBV · insidermonkey.com · 19 Oct 2026AbbVie: SKYRIZI (risankizumab) and RINVOQ (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026ABBV · finanznachrichten.de · 17 Oct 2026Pfizer vs. AbbVie: Is the Cheaper Pharma Stock Really the Better Investment?ABBV · insidermonkey.com · 16 Oct 2026
0 headlines in the last 90 days name Azita Saleki-Gerhardt; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.